{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:27:50Z","timestamp":1771306070739,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combined therapy with venetoclax and hypomethylating agents has significantly improved the outcome of unfit patients ineligible for intensive chemotherapy. A recently published exploratory analysis of the VIALE-A trial reported that up to 51% of patients achieving remission survived more than 2 years. These data along with those from reallife settings, lead to questioning how long it is appropriate to continue treatment in long-term survivors. Accordingly, recent retrospective studies suggested the feasibility of suspending therapy in selected patients while maintaining prolonged responses. Also, these studies showed that retreatment may induce a second remission in almost a third of patients. We report the case of a patient who received salvage therapy with venetoclax and azacytidine, that was discontinued few cycles after blasts clearance because of severe hematological toxicity. Despite suspension, he maintained a sustained response lasting almost one year and was successfully retreated with the same combination when a second relapse occurred.<\/jats:p>","DOI":"10.1007\/s00277-024-05922-6","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T08:01:53Z","timestamp":1722672113000},"page":"4309-4311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report"],"prefix":"10.1007","volume":"103","author":[{"given":"E.","family":"Tamellini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Simio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bernardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vatteroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Macaluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tanasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"7","key":"5922_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"4","key":"5922_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow\u2010up of <\u2009scp\u2009>\u2009VIALE\u2010A: Venetoclax and azacitidine in chemotherapy\u2010ineligible untreated acute myeloid leukemia. Am J Hematol 99(4):615\u2013624. https:\/\/doi.org\/10.1002\/ajh.27246","journal-title":"Am J Hematol"},{"issue":"13","key":"5922_CR3","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","volume":"6","author":"CC Chua","year":"2022","unstructured":"Chua CC, Hammond D, Kent A et al (2022) Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879\u20133883. https:\/\/doi.org\/10.1182\/bloodadvances.2022007083","journal-title":"Blood Adv"},{"issue":"4","key":"5922_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J et al (2024) Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy. Blood 143(4):336\u2013341. https:\/\/doi.org\/10.1182\/blood.2023021579","journal-title":"Blood"},{"issue":"10","key":"5922_CR5","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3324\/haematol.2023.282681","volume":"108","author":"JA Gutman","year":"2023","unstructured":"Gutman JA, Winters A, Kent A et al (2023) Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica 108(10):2616\u20132625. https:\/\/doi.org\/10.3324\/haematol.2023.282681","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"5922_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2023-185437","volume":"142","author":"S Garciaz","year":"2023","unstructured":"Garciaz S, Bertoli S, Sallman DA et al (2023) Acute myeloid leukemia patients who stopped Venetoclax or\/and Azacytidine for other reasons than Progression have a prolonged treatment free remission and overall survival. A Filo Study. Blood 142(Supplement 1):161\u2013161. https:\/\/doi.org\/10.1182\/blood-2023-185437","journal-title":"Blood"},{"issue":"11","key":"5922_CR7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00277-022-04938-0","volume":"101","author":"OG Sevindik","year":"2022","unstructured":"Sevindik OG, Mergen M, Mergen S, Mutlu YG, Ayd\u0131n BB, Serin I (2022) To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Ann Hematol 101(11):2545\u20132547. https:\/\/doi.org\/10.1007\/s00277-022-04938-0","journal-title":"Ann Hematol"},{"issue":"14","key":"5922_CR8","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1080\/10428194.2020.1808213","volume":"61","author":"TA Othman","year":"2020","unstructured":"Othman TA, Zhang J, Mei M et al (2020) Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. Leuk Lymphoma 61(14):3532\u20133533. https:\/\/doi.org\/10.1080\/10428194.2020.1808213","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05922-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05922-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:05:39Z","timestamp":1729933539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05922-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5922"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05922-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"29 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical review and approval were waived for this case report with no formal analysis aiming to evaluate the efficacy of a therapeutic approach. The patient has provided written informed consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}